The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
Open accessAbstract
Introduction: Major depressive disorder (MDD) is one of the most common mental disorders worldwide, estimated to affect 10–15% of the population per year. Treatment resistant depression (TRD) is estimated to affect a third of these patients who show difficulties in social and occupational function, decline of physical health, suicidal thoughts and increased health care utilization. We describe the prevalence of MDD, TRD and associated healthcare resource utilization in Maccabi Healthcare Services (MHS), a 2.5 million-member state-mandated health service in Israel. Methods: All MHS members with an MDD diagnosis were identified within the years 2017–2018 and prevalence assessed by age, sex and TRD. To assess the incidence of MDD, members aged 18–65 years at the start of any MDD episode were identified between 1 st January 2016 and 31 st May 2018 with at least one systemic first-line antidepressant treatment within three months before or after the initial episode. Treatment patterns, time on first-line treatment, and healthcare resource utilization were compared by TRD. Results: A total of 4960 eligible MDD patients were identified (median age = 51 years, 65% female), representing a period prevalence of 0.218%, and of those, a high proportion of patients received drug treatment (92%). Among incident MDD cases (n = 2553), 24.4% had TRD. Factors associated with TRD included increasing age and personality disorder. Median time on treatment was 3.7 months (longer for those without TRD than those with) and 81.9% of patients purchased more than one month’s supply of therapy. In the year after index, patients with TRD had a significant increased number of visits to primary care physicians, psychiatrists, emergency room visits, general hospitalizations, and psychiatric hospitalizations. Conclusion: Our study shows that prevalence of MDD in Israel is low compared to other countries, however once diagnosed, patients' are likely to receive drug treatment. Among patients diagnosed with MDD, the proportion of TRD is similar to other countries, increases with age and is associated with increased healthcare utilization, therefore should be a focus of continued research for finding effective long term treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“It is currently estimated that at least 30% of persons with depression meet this definition.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [101]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TRD is often stated to af fect approximately 30% of persons receiving antidepressant treatment in research set tings, while its prevalence in real world prac- tice is estimated to range between 6 and 55% 32,98- 101 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [101]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“In addition, comorbidity was measured by the Deyo-Charlson Comorbidity Index [35] and augmented using the MHS chronic disease registries.”
MethodKessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Seedat, S., Scott, K. M., Angermeyer, M. C., Berglund, P., Bromet, E. J., Brugha, T. S., Demyttenaere, K., de Girolamo, G., Haro, J. M., Jin, R., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.36 · Cited by 1,518
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Katon, W. J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00273-7 · Cited by 1,223
Undertreatment of people with major depressive disorder in 21 countries
Thornicroft, G., Chatterji, S., Evans-Lacko, S., Gruber, M., Sampson, N., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Andrade, L., Borges, G., et al. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.188078 · Cited by 1,121 · cited 1×
“In real-world clinics, not all patients will receive treatment or move to another line of therapy, however we found that untreated patients made up just 3–20% of the entire prevalence cohort (depending on age group and sex), lower than observed in other countries [41].”
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Research works printed but not linked: 1
- (APA) APA. Practice guidelines for the treatment of patients with major depressive disorder, 3rd edition. 2010 [Available from: http://psychiatryonline.org/guidelines.
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
The impact of exercise on depression: how moving makes your brain and body feel better
Hossain, M. N., Lee, J., Choi, H., Kwak, Y.-S., & Kim, J. (2024) · Physical Activity and Nutrition · doi:10.20463/pan.2024.0015 · Cited by 137
Prefrontal cortex astroglia modulate anhedonia-like behavior
Codeluppi-Arrowsmith, S. A., Xu, M., Bansal, Y., Lepack, A. E., Duric, V., Chow, M., Muir, J., Bagot, R. C., Licznerski, P., Wilber, S. L., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02246-1 · Cited by 47
Vincenzo, M. D., Martiadis, V., Rocca, B. D., Arsenio, E., D’Arpa, A., Volpicelli, A., Luciano, M., Sampogna, G., & Fiorillo, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1394787 · Cited by 42
The prevalence and economic burden of treatment-resistant depression in Thailand
Prasartpornsirichoke, J., Pityaratstian, N., Poolvoralaks, C., Sirinimnualkul, N., Ormtavesub, T., Hiranwattana, N., Phonsit, S., & Rungnirundorn, T. (2023) · BMC Public Health · doi:10.1186/s12889-023-16477-y · Cited by 19
Metadata
- Authors
- Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O.
- Affiliations
- Tel Aviv University (IL)
- Maccabi Healthcare Services (IL)
- Venue
- BMC Psychiatry
- Published
- 2022-08-11
- Volume
- 22
- Issue
- 1
- Pages
- 541-541
- ISSN
- 1471-244X (ISSN-L)
- PMC
- PMC9367052
- OpenAlex
- W4290991902
- Cited by
- 23
- References
- 63
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 8 · 2023: 7
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- treatment-resistant depression, major depressive disorder, prevalence, healthcare resource utilization, time on treatment, personality disorders, age as risk factor, psychiatric hospitalization, emergency department visits, Maccabi Healthcare Services, Israel
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Female, Humans, Israel, Male, Middle Aged, Retrospective Studies, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology of treatment resistant depression among major depressive disorder patients in Israel. https://app.cochat.ai/papers/10.1186/s12888-022-04184-8
- The paper
- Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O. (2022). Epidemiology of treatment resistant depression among major depressive disorder patients in Israel. BMC Psychiatry. https://doi.org/10.1186/s12888-022-04184-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.